- Conditions
- Metastatic Cancer, Prostate Cancer
- Interventions
- atrasentan hydrochloride, docetaxel, prednisone, placebo
- Drug · Other
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 1,038 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2016
- U.S. locations
- 554
- States / cities
- Mobile, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 378 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 457–480
of 953
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Urinary Bladder, Overactive
- Interventions
- Fesoterodine 8 mg, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 990 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 109
- States / cities
- Birmingham, Alabama • Fairhope, Alabama • Chandler, Arizona + 80 more
- Conditions
- Diffuse Large B-Cell Lymphoma
- Interventions
- Rituximab, Obinutuzumab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,418 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Tucson, Arizona + 32 more
- Conditions
- Chronic Total Occlusion of Coronary Artery, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease, Coronary Restenosis
- Interventions
- placebo + aspirin, clopidogrel + aspirin OR prasugrel + aspirin, XIENCE V Everolimus Eluting Coronary Stent System (XIENCE V EECSS)
- Drug · Device
- Lead sponsor
- Abbott Medical Devices
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 870 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 144
- States / cities
- Birmingham, Alabama • Fairhope, Alabama • Scottsdale, Arizona + 126 more
- Conditions
- Pediatric Crohn's Disease
- Interventions
- Methotrexate, Sugar pill (placebo)
- Drug · Other
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- Up to 20 Years
- Enrollment
- 306 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Alto, California • New Haven, Connecticut + 27 more
- Conditions
- Lung Cancer
- Interventions
- Prophylactic cranial irradiation, 2.5 Gy fx, Prophylactic cranial irradiation, 2.0 Gy fx, Prophylactic cranial irradiation, 1.5 Gy fx
- Radiation
- Lead sponsor
- Radiation Therapy Oncology Group
- Network
- Eligibility
- Up to 120 Years
- Enrollment
- 265 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2013
- U.S. locations
- 217
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 160 more
- Conditions
- SARS-CoV-2
- Interventions
- mRNA-1273, Placebo
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30,415 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 100
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 79 more
- Conditions
- Ulcerative Colitis
- Interventions
- SHR0302, Placebo
- Drug
- Lead sponsor
- Reistone Biopharma Company Limited
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 368 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 23
- States / cities
- Dothan, Alabama • Lancaster, California • New Haven, Connecticut + 19 more
- Conditions
- Nonalcoholic Steatohepatitis
- Interventions
- SEL, Placebo to match SEL 6 mg, Placebo to match SEL 18 mg
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 883 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 128
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 93 more
- Conditions
- Pulmonary Disease, Chronic Obstructive, COPD, Lung Diseases, Obstructive
- Interventions
- Indacaterol, Formoterol (12 µg b.i.d.), Tiotropium (18 µg o.d.), Placebo to Indacaterol, Placebo to Formoterol
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 2,059 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 221
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Homewood, Alabama + 163 more
- Conditions
- Tuberous Sclerosis Complex
- Interventions
- Ganaxolone, Placebo
- Drug
- Lead sponsor
- Marinus Pharmaceuticals
- Industry
- Eligibility
- 1 Year to 65 Years
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 23
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Orange, California + 20 more
- Conditions
- Thoracoabdominal Aneurysm
- Interventions
- GORE Excluder Thoracoabdominal Branch Endoprosthesis
- Device
- Lead sponsor
- W.L.Gore & Associates
- Industry
- Eligibility
- 19 Years and older
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 34 more
- Conditions
- Heart Failure
- Interventions
- MultiPoint Pacing, Traditional Biventricular Pacing
- Device
- Lead sponsor
- Abbott Medical Devices
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 506 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 49
- States / cities
- Huntsville, Alabama • Mesa, Arizona • Little Rock, Arkansas + 44 more
- Conditions
- Pouchitis
- Interventions
- Vedolizumab Placebo, Ciprofloxacin, Vedolizumab
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 10
- States / cities
- Chicago, Illinois • Evanston, Illinois • Minneapolis, Minnesota + 7 more
- Conditions
- Estrogen Receptor Negative Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Triple Negative Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer, Triple-negative Breast Cancer
- Interventions
- cisplatin, laboratory biomarker analysis, pharmacological study, dynamic contrast-enhanced MRI, diffusion-weighted MRI & chemical exchange saturation transfer MRI, GDC -0941
- Drug · Other · Procedure
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 13 more
- Conditions
- Moderately to Severely Active Crohns Disease
- Interventions
- Afimkibart, Placebo
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 16 Years to 80 Years
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2033
- U.S. locations
- 95
- States / cities
- Dothan, Alabama • Phoenix, Arizona • Sun City, Arizona + 79 more
- Conditions
- Sickle Cell Disease
- Interventions
- NDec - oral decitabine-tetrahydrouridine, HU - Hydroxyurea, Placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 53
- States / cities
- Mobile, Alabama • Los Angeles, California • Oakland, California + 37 more
- Conditions
- Lung Cancer
- Interventions
- Paclitaxel, Carboplatin, Bevacizumab, Pemetrexed Disodium Heptahydrate
- Drug · Biological
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 1,516 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2021
- U.S. locations
- 434
- States / cities
- Anniston, Alabama • Fairbanks, Alaska • Fairfield, California + 312 more
- Conditions
- Ulcerative Colitis
- Interventions
- RPC1063, Placebo
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1,012 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 113
- States / cities
- Sun City, Arizona • Tucson, Arizona • North Little Rock, Arkansas + 87 more
- Conditions
- Endometrial Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Endometrioid Adenocarcinoma, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8
- Interventions
- Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy, Capivasertib, Cediranib Maleate, Computed Tomography, Durvalumab, Echocardiography Test, Multigated Acquisition Scan, Olaparib
- Procedure · Drug · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 288 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 760
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 481 more
- Conditions
- Osteosarcoma in Children, Osteosarcoma in Adolescents and Young Adults
- Interventions
- High-dose Methotrexate
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 7 Years to 22 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 9
- States / cities
- Chapel Hill, North Carolina • Charlotte, North Carolina • Durham, North Carolina + 5 more
- Conditions
- Breast Cancer
- Interventions
- therapeutic conventional surgery, whole breast irradiation
- Procedure · Radiation
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 40 Years and older · Female only
- Enrollment
- 270 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2023
- U.S. locations
- 350
- States / cities
- Hot Springs, Arkansas • Dublin, California • Emeryville, California + 216 more
- Conditions
- Systemic Lupus Erythematosus, Active Cutaneous Lupus Erythematosus
- Interventions
- BIIB059 (litifilimab), Placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 264 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 53
- States / cities
- Anniston, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 44 more
- Conditions
- Gastroesophageal Reflux Disease (GERD), Reflux, Gastroesophageal, Gastroesophageal Reflux, Acid Reflux
- Interventions
- Laparoscopic implantation surgery with or without crural repair, EndoStim stimulation for first six months of study, EndoStim stimulation from Month 6 thru end of study, Sham EndoStim stimulation for first six months of study
- Procedure · Device
- Lead sponsor
- EndoStim Inc.
- Industry
- Eligibility
- 22 Years to 75 Years
- Enrollment
- 161 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 18
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 13 more